BridgeBio (BBIO) Director Reports Option Exercise and Same-Day Sale on 09/05/2025

Rhea-AI Filing Summary

Frank McCormick, a director of BridgeBio Pharma, Inc. (BBIO), reported transactions dated 09/05/2025. On that date he exercised a stock option to acquire 74,000 shares at an exercise price of $11.92 per share. He also sold 74,000 shares with a weighted average sale price of $53.156 per share (range $52.96–$53.39). After the reported transactions the Form 4 shows 83,275 shares owned directly, 879,979 shares owned indirectly by the Francis P. McCormick Rev Trust, and 84,814 shares underlying options held directly.

Positive

• Exercise of 74,000 options at a stated exercise price of $11.92 was disclosed
• Detailed price range provided for shares sold ($52.96–$53.39) with weighted average sale price $53.156
• Indirect ownership clearly disclosed: 879,979 shares held by the Francis P. McCormick Rev Trust

Negative

• Sale of 74,000 shares was reported the same day as the option exercise, reducing direct holdings to 83,275 shares
• No breakdown in the filing of the exact number of shares sold at each price within the disclosed price range (only weighted average provided)

Insights

Securities Analyst

TL;DR Director exercised options and sold an equal number of shares the same day, net direct holdings changed as reported.

The filing documents a same-day option exercise of 74,000 shares at $11.92 and an immediate sale of 74,000 shares at a weighted average of $53.156. This is a clear disclosable Section 16 transaction showing conversion of option exposure into cash while retaining substantial indirect holdings via a family trust. The numbers reported are precise: direct beneficial ownership ended at 83,275 shares and indirect ownership at 879,979 shares, with 84,814 option-based shares remaining outstanding to the reporting person.

Corporate Governance Expert

TL;DR Form 4 properly discloses director transactions and identifies an Attorney-in-Fact signature.

The filing identifies the reporting person as a director and indicates the Form 4 was signed on behalf of the reporting person by an Attorney-in-Fact. It includes an exhibit reference to a Power of Attorney. The disclosure lists both direct and indirect ownership and provides an explicit footnote on the sale price range and vesting schedule for the option, meeting standard Form 4 disclosure practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		M		74,000	A	$11.92	157,275	D
Common Stock	09/05/2025		S		74,000	D	$53.156(1)	83,275	D
Common Stock								879,979	I	By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.92	09/05/2025		M			74,000	(2)	02/20/2033	Common Stock	74,000	$0	84,814	D

Explanation of Responses:

1. Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

2. The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for BBIO and what is their relationship to the company?

The Form 4 was filed for Frank McCormick, who is identified as a director of BridgeBio Pharma, Inc. (BBIO).

What transactions did the reporting person make on 09/05/2025?

On 09/05/2025 the reporting person exercised 74,000 options at $11.92 per share and sold 74,000 shares at a weighted average price of $53.156 per share (range $52.96–$53.39).

What were the reporting person’s holdings after the transactions?

Following the transactions the filing reports 83,275 shares owned directly, 879,979 shares owned indirectly by the Francis P. McCormick Rev Trust, and 84,814 shares underlying options owned directly.

What is the exercise and vesting detail for the option exercised?

The exercised stock option had an exercise price of $11.92 and vests in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to continued board service.

Is additional price detail available for the shares sold?

The filing discloses a weighted average sale price of $53.156 and states the sale prices ranged from $52.96 to $53.39; the filer offered to provide the per-price breakdown upon request.

Who signed the Form 4?

The Form 4 is signed by Will Solis, Attorney-in-Fact on behalf of the reporting person, and the filing references an Exhibit 24 Power of Attorney.